系统性炎症指标对下肢动脉硬化闭塞症患者发生肌少症的预测价值

摘要
图/表
参考文献(0)
相关文章 (15)

全文: PDF (1697 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

文章导读

摘要目的：评估全身免疫炎症指数（SII）、血小板/淋巴细胞比值（PLR）、中性粒细胞/淋巴细胞比值（NLR）、淋巴细胞/单核细胞比值（LMR）和C反应蛋白（CRP）等系统性炎症指标对下肢动脉硬化闭塞症（ASO）患者发生肌少症的预测价值。方法：本研究纳入江苏大学附属武进医院和南京医科大学附属常州第二人民医院的251例ASO患者。依据第三腰椎腰大肌指数（PMI）将患者分为肌少症组和非肌少症组。收集患者的一般资料和相关血液指标，并计算SII、PLR、NLR和LMR。通过二分类Logistic回归分析确定ASO患者发生肌少症的危险因素，并采用受试者工作特征（ROC）曲线评估相关指标的预测效果。结果： 251例ASO患者中，肌少症组和非肌少症组患者数分别为98例（39.0%）和153例（61.0%）。与非肌少症组相比，肌少症组患者年龄明显增加（P<0.001），SII、PLR、NLR和CRP水平明显增高（P<0.01），而BMI和LMR水平明显降低（P<0.01）。多因素Logistic回归分析结果表明，高龄、BMI偏低、SII上升均为ASO患者发生肌少症的独立危险因素。ROC曲线结果显示，年龄、BMI、SII和3项指标联合预测肌少症发生的曲线下面积分别为0.674、0.678、0.644和0.746（P均<0.001）。结论：年龄、BMI及系统性炎症指标中的SII对ASO患者肌少症的发生有一定的预测价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	聂璐1
	2
	杨启帆3
	郑维淼1
	2
	徐强1
	2

关键词 ： , 系统性炎症指标 83, 179), font-family: ????, font-weight: 700, text-align: -webkit-right, background-color: rgb(212, 226, 255), ')" href="#">">, 下肢动脉硬化闭塞症 83, 179), font-family: ????, font-weight: 700, text-align: -webkit-right, background-color: rgb(212, 226, 255), ')" href="#">">, 肌少症

Abstract： Objective： To assess the predictive value of systemic inflammatory indicators, including systemic immune-inflammation index (SII), platelet to lymphocyte ratio (PLR), neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), and C-reactive protein (CRP), for the onset of sarcopenia in patients with lower extremity arteriosclerosis obliterans (ASO). Methods： A total of 251 ASO patients from the Wujin Hospital Affiliated with Jiangsu University and the Second People′s Hospital Affiliated with Nanjing Medical University were included in the study. Patients were classified into sarcopenia and non-sarcopenia groups based on the psoas muscle index (PMI) of the third lumbar vertebra. Relevant blood indicators of the patients were collected, and SII, PLR, NLR, and LMR were calculated. Binary Logistic regression analysis was used to identify the risk factors for sarcopenia, and the predictive performance of each indicator was assessed by using the receiver operating characteristic (ROC) curve. Results： Among the 251 ASO patients, there were 98 (39.0%) in the sarcopenia group and 153 (61.0%) in the non-sarcopenia group. Compared with the non-sarcopenia group, the age of patients in the sarcopenia group was significantly increased (P<0.001), and the levels of SII, PLR, NLR and CRP were significantly increased (P<0.01), and the levels of BMI and LMR were significantly decreased (P<0.01). Multivariate Logistic analysis revealed that advanced age, low BMI, elevated SII were independent risk factors for sarcopenia. The ROC curve further confirmed the predictive value of these indicators for sarcopenia, with the area under the curve (AUC) of age, BMI, SII, and combined prediction of 3 indicators for the onset of sarcopenia being 0.674, 0.678, 0.644, and 0.746 respectively (all P<0.001). Conclusion： Age, BMI, and systemic inflammatory indicators such as SII have predictive value for the onset of sarcopenia in ASO patients.

Key words：

收稿日期: 2023-09-02

基金资助: 江苏省新药研究与临床药学重点实验室开放项目(XZSYSKF2021038)；常州市高层次医学人才培养项目(2022CZBJ108)

通讯作者: 徐强（通讯作者），主任医师，硕士生导师，E-mail: wjxuqiang@163.com

作者简介: 江苏省新药研究与临床药学重点实验室开放项目(XZSYSKF2021038)；常州市高层次医学人才培养项目(2022CZBJ108)

引用本文:

聂璐1，2，杨启帆3，郑维淼1，2，徐强1，2. 系统性炎症指标对下肢动脉硬化闭塞症患者发生肌少症的预测价值[J]. 江苏大学学报:医学版, 2024, 24(01): 74-78. NIE Lu1,2, YANG Qifan3, ZHENG Weimiao1,2, XU Qiang1,2. Predictive value of systemic inflammatory markers for the onset of sarcopenia in patients with lower extremity arteriosclerosis obliterans

. Journal of Jiangsu University(Medicine Edition), 2024, 24(01): 74-78.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2024/V24/I01/74

［1］下肢动脉硬化闭塞症诊治指南［J］. 中华普通外科学文献（电子版）, 2016, 10（1）: 1-18.

［2］Tsai PS, Lin DC, Jan YT, et al. Lowerextremity muscle wasting in patients with peripheral arterial disease: quantitative measurement and evaluation with CT［J］. Eur Radiol, 2023, 33(6): 4063-4072.

［3］CruzJentoft AJ, Sayer AA. Sarcopenia［J］. Lancet, 2019, 393(10191): 2636-2646.

［4］Cevei M, Onofrei RR, Cioara F, et al. Correlations between the quality of life domains and clinical variables in sarcopenic osteoporotic postmenopausal women［J］. J Clin Med, 2020, 9(2): 441.

［5］Shafiee G, Keshtkar A, Soltani A, et al. Prevalence of sarcopenia in the world: a systematic review and metaanalysis of general population studies［J］. J Diabetes Metab Disord, 2017, 16: 21.

［6］Pizzimenti M, Meyer A, Charles AL, et al. Sarcopenia and peripheral arterial disease: a systematic review［J］. J Cachexia Sarcopenia Muscle, 2020, 11(4): 866-886.

［7］Matsubara Y, Matsumoto T, Inoue K, et al. Sarcopenia is a risk factor for cardiovascular events experienced by patients with critical limb ischemia［J］. J Vasc Surg, 2017, 65(5): 1390-1397.

［8］Sugai T, Watanabe T, Otaki Y, et al. Decreased psoas muscle computed tomography value predicts poor outcome in peripheral artery disease［J］. Circ J, 2018, 82(12): 3069-3075.

［9］郦俊生, 宋云霄, 程捷. 治疗前PLR、NLR和LMR在预测前列腺癌预后中的价值［J］. 检验医学, 2021, 36（6）: 631-636.

［10］余建洪, 刘钰. 自贡地区成人外周血SII、NLR、dNLR、 PLR及LMR参考区间的建立［J］. 检验医学, 2019, 34（7）: 630-632.

［11］Liu YY, Ruan GT, Ge YZ, et al. Systemic inflammation with sarcopenia predicts survival in patients with gastric cancer［J］. J Cancer Res Clin Oncol, 2023, 149(3): 1249-1259.

［12］Hu Q, Mao W, Wu T, et al. High neutrophiltolymphocyte ratio and platelettolymphocyte ratio are associated with sarcopenia risk in hospitalized renal cell carcinoma patients［J］. Front Oncol, 2021, 11: 736640.

［13］CruzJentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis［J］. Age Ageing, 2019, 48(1): 16-31.

［14］Seluk N, Albeyogˇlu ??塁, Bastopcu M, et al. Sarcopenia is a risk factor for major adverse cardiac events after surgical revascularization for critical limb ischemia［J］. Vascular, 2023, 31(1): 64-71.

［15］Pizzimenti M, Charles AL, Riou M, et al. Usefulness of platelettolymphocyte ratio as a marker of sarcopenia for critical limb threatening ischemia［J］. Ann Vasc Surg, 2021, 72: 72-78.

［16］Volpato S, Bianchi L, Cherubini A, et al. Prevalence and clinical correlates of sarcopenia in communitydwelling older people: application of the EWGSOP definition and diagnostic algorithm［J］. J Gerontol A Biol Sci Med Sci, 2014, 69(4): 438-446.

［17］Rolland Y, Czerwinski S, Abellan Van Kan G, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives［J］. J Nutr Health Aging, 2008, 12(7): 433-450.

［18］Beaudart C, Rizzoli R, Bruyère O, et al. Sarcopenia: burden and challenges for public health［J］. Arch Public Health, 2014, 72(1): 45.

［19］Matsubara Y, Matsumoto T, Aoyagi Y, et al. Sarcopenia is a prognostic factor for overall survival in patients with critical limb ischemia［J］. J Vasc Surg, 2015, 61(4): 945-950.

［20］Zamboni M, Mazzali G, Fantin F, et al. Sarcopenic obesity: a new category of obesity in the elderly［J］. Nutr Metab Cardiovasc Dis, 2008, 18(5): 388-395.

［21］Choi KM. Sarcopenia and sarcopenic obesity［J］. Korean J Intern Med, 2016, 31(6): 1054-1060.

［22］王亚洲, 刘慧玲. 血流感染患者血小板参数的变化［J］. 检验医学, 2021, 36（5）: 514-516.

［23］邹小红, 凌利芬, 刘小晴, 等. NLR和SII在不同类型血流感染中的诊断价值［J］. 检验医学与临床, 2021, 18（17）: 2501-2503.

［24］乔建兵, 戴宏宇, 徐春华, 等. 炎症因子评分对晚期非小细胞肺癌患者预后评估的应用价值［J］. 江苏大学学报(医学版), 2019, 29(5): 430-435.

［25］Okugawa Y, Toiyama Y, Yamamoto A, et al. Close relationship between immunological/inflammatory markers and myopenia and myosteatosis in patients with colorectal cancer: a propensity score matching analysis［J］. JPEN J Parenter Enteral Nutr, 2019, 43(4): 508-515.［